

Estudio Propio: **MÁSTER EN ENFERMEDAD INFLAMATORIA INTESTINAL PARA ENFERMERÍA**

Código Plan de Estudios: **EO64**

Año Académico: **2020-2021**

ESTRUCTURA GENERAL DEL PLAN DE ESTUDIOS:							
CURSO	Obligatorios		Optativos		Prácticas Externas	Memoria/ Proyecto	Créditos
	Créditos	Nº Asignaturas	Créditos	Nº Asignaturas	Créditos	Créditos	
1º	54	1				6	60
2º							
3º							
ECTS TOTALES	54	1				6	60

PROGRAMA TEMÁTICO:				
ASIGNATURAS OBLIGATORIAS				
Código Asignatura	Curso	Denominación	Carácter OB/OP	Créditos
706010	1	ENFERMEDAD INFLAMATORIA INTESTINAL PARA ENFERMERÍA	OB	54
MEMORIA /PROYECTO/TRABAJO FIN DE MÁSTER				
Código Asignatura	Curso	Denominación	Carácter OB/OP	Créditos
706011	1	TRABAJO FIN DE MÁSTER	OB	6

Carácter: OB - Obligatoria; OP – Optativa

GUÍA DOCENTE

Año académico	2020/2021	
Estudio	Máster en Enfermedad Inflamatoria Intestinal para Enfermería (EO64)	
Nombre de la asignatura	ENFERMEDAD INFLAMATORIA INTESTINAL PARA ENFERMERÍA	
Carácter (Obligatoria/Optativa)	Obligatoria	
Créditos (1 ECTS=25 horas)	54	
Modalidad (elegir una opción)	<input type="checkbox"/>	Presencial
	<input type="checkbox"/>	Semipresencial
	<input checked="" type="checkbox"/>	On-line
Profesor/a responsable	Melchor Álvarez de Mon Soto	
Idioma en el que se imparte	Español	

DISTRIBUCIÓN DE CRÉDITOS (especificar en horas)

Número de horas presenciales/on-line asistencia profesor/a	430
Número de horas de trabajo personal del estudiante	920
Total horas	1350

CONTENIDOS (Temario)

Módulo 1: PRINCIPIOS GENERALES DE EII: ENFERMEDAD DE CROHN y COLITIS ULCEROSA: DIFERENCIAS Y SIMILITUDES

I. Introducción:

- Epidemiología
- Etiopatogenia
- Fisiopatología
- Factores ambientales
- Clasificación

II. Manifestaciones clínicas

III. Comorbilidades

IV. Métodos de diagnóstico

Módulo 2: PRINCIPIOS GENERALES DEL TRATAMIENTO DE LAS EII

Mesalazinas

- Efectos adversos
- Interacciones farmacológicas
- Seguimiento del tratamiento
- Evaluación de la respuesta

II. Corticoides

- Efectos adversos
- Interacciones farmacológicas
- Seguimiento del tratamiento
- Evaluación de la respuesta

III. Inmunosupresores

- Efectos adversos
- Interacciones farmacológicas
- Seguimiento del tratamiento
- Evaluación de la respuesta

IV. Biológicos

- Efectos adversos
- Interacciones farmacológicas
- Seguimiento del tratamiento
- Evaluación de la respuesta
- Biosimilares

V. Nuevas moléculas y otras alternativas

VI. Tratamiento en situaciones especiales

- Embarazo
- Pediatría

VI. Tratamiento del dolor

VII. Tratamiento quirúrgico

Indicaciones

Tipos de cirugía

VIII. Algoritmo-Esquema de Manejo del paciente con CU y EC

Módulo 3: CUIDADOS DEL PACIENTE OSTOMIZADO EN LA EII

- I. ¿Qué es una ostomía?
- II. Tipos de ostomías
- III. Cuidados del estoma. Educación del paciente ostomizado
- IV. Tipos de dispositivos o bolsas. ¿Cómo elegir el más adecuado?
- V. Complicaciones del estoma
- VI. Consejos generales
 - Dieta
 - Deporte
 - Vida social
 - Viajes

Módulo 4: EDUCACIÓN PARA LA SALUD DEL PACIENTE CON EII

- I. Cuestionarios para medir la calidad de vida
- II. Nutrición
- III. Ejercicio
- IV. Vacunas – estado inmunológico de los pacientes
- V. Viajes y EII
- VI. Hábito tabáquico
- VII. Adhesión al tratamiento
- VIII. Sexualidad y embarazo

Módulo 5: APOYO PSICOSOCIAL AL PACIENTE CON EII

- I. Emociones de los pacientes con EII
- II. Transición del paciente pediátrico a paciente adulto
- III. Terapia del control del estrés
- IV. Terapia de relajación
- V. Estrategias de afrontamiento
- VI. Apoyo social
- VII. Comunicación y entrevista motivacional

VIII. Redes sociales

Módulo 6: SEGUIMIENTO DEL PACIENTE CON EII (8 ECTS)

I. Seguimiento del paciente con EII

- Visita de acogida
- Atención telemática
- Cambios o inicio de tratamientos
- Tratamientos subcutáneos
- Tratamientos endovenosos
- Actuación ante el brote agudo

II. Cuidados del paciente hospitalizado y postcirugía.

III. Manejo de la anemia y déficits vitamínicos por enfermería

IV. Embarazo y EII

V. Paciente pediátrico

Módulo 7: UNIDAD INTEGRAL DE EII

I. Estructura de una Unidad Integral de EII

II. Atención multidisciplinar - Papel de los especialistas

III. Papel de enfermería especializada

IV: Gestión de casos

IV. Comunicación

V. Enfermedades Inmunomediadas

VI. Unidades Integrales

Módulo 8: INVESTIGACIÓN EN EII

I. Trabajos científicos

II. Ensayos clínicos

III. Difusión, redacción de artículos científicos

IV. Actualización bases de datos

V. Metodología

VI. Requerimientos Legales

EVALUACIÓN

Superación de la evaluación tipo test final de cada módulo con un 70% de respuestas acertadas. Los exámenes consistirán en exámenes tipo test con 4 posibles respuestas de las cuales solo una es correcta. Deberá superar todos los exámenes para considerarse aprobada la asignatura.

BIBLIOGRAFÍA

Regueiro M, Loftus EV, Steinhart AH, Cohen RD. "Medical management of left side ulcerative colitis and ulcerative proctitis:critical evaluation of therapeutic trials". *Inflamm Bowel Dis.* 2006;12:979-94.

Sutherland L, Macdonald JK. "Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis". *Cochrane Database Syst Rev.* 2006;2: CD000543.

Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, et al. "Delayed-release oral mesalamine 4.8 g/day (800 mg Tablet) is effective for patients with moderately active ulcerative colitis". *Gastroenterology.* 2009;137:1934-43.

Marshall J, Irvine J. "Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis". *Am J Gastroenterol.* 2000;95:1628-36.

- Bergman R, Parkes. "Systematic review: the use of mesalazine in inflammatory bowel disease". *Aliment Pharmacol Ther.* 2006;23:841-55.
- Tromm A, Bunganic I, Tomsova E, et al. "Double-blind, double-dummy, randomised, multicentre study to compare the efficacy and safety of oral budesonide (9 mg) and oral mesalazine (4.5 g) in moderately active Crohn's disease patients". *Gastroenterology* 2009;139(Suppl1):391
- Akobeng AK, Thomas AG. "Enteral nutrition for maintenance of remission in Crohn's disease". *Cochrane Database Syst Rev* 2007;3:CD005984.
- Steinhart A.H., Forbes A., Mills E.C., et al. "Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease". *Aliment Pharmacol Ther* 25, 2007: 1389–1399.
- Marshall JK, Irvine EJ. "Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis". *Gut.* 1997;40:775-81.
- Truelove SC, Witts LJ. "Cortisone in ulcerative colitis. Final report on a therapeutic trial". *BMJ.* 1955;2:1041-8.
- Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. "Oral budesonide for induction of remission in ulcerative colitis". *Cochrane Database Syst Rev* 2010 [CD007698-CD007698].
- Turner D, Walsh CM, Steinhart AH, Griffiths AM. "Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression". *Clin Gastroenterol Hepatol.* 2007;5:103-10
- Otley A, Steinhart AH. "Budesonide for induction of remission in Crohn's disease". *Cochrane Database Syst Rev* Oct 19 2005(4): CD000296 Review.
- Benchimol EI, Seow CH, Otley AR, Steinhart AH. "Budesonide for maintenance of remission in Crohn's disease". *Cochrane Database Syst Rev* 2009;1:CD002913.
- Rahimi R, Nikfar S, Rezaie A, Abdollahi M. "A Meta-analysis of antibiotic therapy for active ulcerative colitis". *Dig Dis Sci.* 2007;52:2920-5.
- Selby W, Pavli P, Crotty B. "Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease". *Gastroenterology* 2007;132:2313–9.
- Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *The American Journal of Gastroenterology.* 2018;113(4):481-517. 10.1038/ajg.2018.27
- Cantoro L, Di Sabatino A, Papi C, Margagnoni G, Ardizzone S, Giuffrida P, et al. The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study. *J Crohns Colitis.* 2017;11(8):975-80. 10.1093/ecco-jcc/jjx041 28333328
- 3Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, et al. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. *J Crohns Colitis.* 2015;9(8):601-6. 10.1093/ecco-jcc/jjv067 25908718
- Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2015;21(8):1982-92. 10.1097/mib.0000000000000392 10.1097/MIB.0000000000000392.
- 5Sanz J, Juanola Roura X, Seoane-Mato D, Montoro M, Gomollon F. Screening of Inflammatory Bowel Disease and Spondyloarthritis for Referring Patients Between Rheumatology and Gastroenterology. *Gastroenterol Hepatol.* 2018;41(1):54-62. 10.1016/j.gastrohep.2017.03.012 10.1016/j.gastrohep.2017.03.012. Epub 2017 Sep 4.
- Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical

- Management. *Journal of Crohn's and Colitis*. 2017;11(1):3-25. 10.1093/ecco-jcc/jjw168
- Reinisch S, Schweiger K, Pablik E, Collet-Fenetrier B, Peyrin-Biroulet L, Alfaro I, et al. An index with improved diagnostic accuracy for the diagnosis of Crohn's disease derived from the Lennard-Jones criteria. *Aliment Pharmacol Ther*. 2016;44(6):601-11. 10.1111/apt.13727 27466047
- Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *Journal of Crohn's and Colitis*. 2017;11(6):649-70. 10.1093/ecco-jcc/jjx008
- Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. *J Crohns Colitis*. 2013;7(12):982-1018. 10.1016/j.crohns.2013.09.016 24184171
- Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *Am J Gastroenterol*. 2015;110(9):1324-38. 10.1038/ajg.2015.233 26303131
- Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastroenterology*. 2015;148(3):639-51.e28. 10.1053/j.gastro.2015.01.031 25702852
- Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G, et al. A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricture Crohn's Disease. *Inflamm Bowel Dis*. 2017;23(1):133-42. 10.1097/MIB.0000000000000988 28002130
- Bruining DH, Zimmermann EM, Loftus EV, Jr., Sandborn WJ, Sauer CG, Strong SA. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. *Gastroenterology*. 2018;154(4):1172-94. 10.1053/j.gastro.2017.11.274 29329905
- Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. *J Crohns Colitis*. 2013;7(7):556-85. 10.1016/j.crohns.2013.02.020 23583097
- Atkinson NS, Bryant RV, Dong Y, Maaser C, Kucharzik T, Maconi G, et al. WFUMB Position Paper. Learning Gastrointestinal Ultrasound: Theory and Practice. *Ultrasound Med Biol*. 2016;42(12):2732-42. 10.1016/j.ultrasmedbio.2016.08.026 27742140
- Panes J, Bouzas R, Chaparro M, Garcia-Sanchez V, Gisbert JP, Martinez de Guereñu B, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. *Aliment Pharmacol Ther*. 2011;34(2):125-45. 10.1111/j.1365-2036.2011.04710.x 21615440
- Chatu S, Subramanian V, Pollok RC. Meta-analysis: diagnostic medical radiation exposure in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2012;35(5):529-39. 10.1111/j.1365-2036.2011.04975.x 22239831
- Takenaka K, Ohtsuka K, Kitazume Y, Matsuoka K, Nagahori M, Fujii T, et al. Utility of Magnetic Resonance Enterography For Small Bowel Endoscopic Healing in Patients With Crohn's Disease. *Am J Gastroenterol*. 2018;113(2):283-94. 10.1038/ajg.2017.464 29257147
- Rimola J, Planell N, Rodriguez S, Delgado S, Ordas I, Ramirez-Morros A, et al. Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging. *Am J Gastroenterol*. 2015;110(3):432-40. 10.1038/ajg.2014.424 25623654
- Kucharzik T, Wittig BM, Helwig U, Borner N, Rossler A, Rath S, et al. Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. *Clin Gastroenterol Hepatol*. 2016. 10.1016/j.cgh.2016.10.040 27856365
- Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, et al. Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study.

Inflammatory Bowel Diseases. 2014 Dec 1;;20(12):2247-59.

Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, et al. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. *Inflammatory bowel diseases*. 2017;23(4):650-60.

Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, et al. Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*. 2014;12(1):84.e2.

Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, et al. Optimizing Anti-TNF-alpha Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2016 April 01;14(4):557.e2.

Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip J, Genin C, et al. Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. *Inflammatory Bowel Diseases*. 2014 Jul 1;;20(7):1288-95.

Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. *Frontline Gastroenterology*. 2016 Oct;7(4):289-300.

West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude, C J. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. *Aliment Pharmacol Ther*. 2008 November 01;28(9):1122-6.

Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. *Gastroenterology*. 2009 November 01;137(5):1628-40.

Schulze H, Esters P, Hartmann F, Stein J, Christ C, Zorn M, et al. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. *Scand J Gastroenterol*. 2018 March 21:1-7.

Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, et al. Association of Vedolizumab Level, Anti-Drug Antibodies, and alpha4beta7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2018 May 01;16(5):705.e7.

Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, et al. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. *Clin Gastroenterol Hepatol*. 2017 October 01;15(10):1588.e3.

Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. *Inflamm Bowel Dis*. 2014 November 01;20(11):1996-2003.

Papamichael K, Osterman MT, Siegel CA, Melmed GY, Dubinsky MC, Colombel JF, et al. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? *Gastroenterology*. 2018 March 01;154(4):1201-2.

Papamichael K, Vajravelu RK, Vaughn BP, Osterman MT, Cheifetz AS. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. *J Crohns Colitis*. 2018 March 24.

Bloem K, Hernandez-Breijo B, Martinez-Feito A, Rispens T. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context. *Ther Drug Monit*. 2017 August 01;39(4):327-32.

Brandse JF, van den Brink, G R, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. *Gastroenterology*. 2015 August 01;149(2):5.e2.

Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, et al. Postinduction serum infliximab trough

level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. *Gut*. 2014 November 01;63(11):1721-7.

Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis. *J Gastroenterol*. 2016 March 01;51(3):241-51.

Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, et al. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. *Clin Gastroenterol Hepatol*. 2016 April 01;14(4):543-9.

Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten, A, Billiet T, Baert F, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. *Clin Gastroenterol Hepatol*. 2015 March 01;13(3):531-8.

Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, et al. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. *J Crohns Colitis*. 2016 July 11.

GUÍA DOCENTE

Año académico	2020/2021	
Estudio	Máster en Enfermedad Inflamatoria Intestinal para Enfermería (EO64)	
Nombre de la asignatura	TRABAJO FIN DE MÁSTER	
Carácter (Obligatoria/Optativa)	OB	
Créditos (1 ECTS=25 horas)	6	
Modalidad (elegir una opción)		Presencial
		Semipresencial
	X	On-line
Profesor/a responsable	Melchor Álvarez de Mon Soto	
Idioma en el que se imparte	Español	

DISTRIBUCIÓN DE CRÉDITOS (especificar en horas)

Número de horas presenciales/on-line asistencia profesor/a	50
Número de horas de trabajo personal del estudiante	100
Total horas	150

CONTENIDOS (Temario)

Realización de un Trabajo fin de master cuyo tema será acordado por el tutor de cada alumno

EVALUACIÓN

Se evaluará el trabajo realizado así como su defensa y presentación ante el tribunal del TFM

BIBLIOGRAFÍA

Regueiro M, Loftus EV, Steinhart AH, Cohen RD. "Medical management of left side ulcerative colitis and ulcerative proctitis:critical evaluation of therapeutic trials". *Inflamm Bowel Dis.* 2006;12:979-94.

Sutherland L, Macdonald JK. "Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis". *Cochrane Database Syst Rev.* 2006;2: CD000543.

Sandborn WJ, Regula J, Feagan BG, Belousova E, Jojic N, Lukas M, et al. "Delayed-release oral mesalamine 4.8 g/day (800 mg Tablet) is effective for patients with moderately active ulcerative colitis". *Gastroenterology.* 2009;137:1934-43.

Marshall J, Irvine J. "Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis". *Am J*

Gastroenterol. 2000;95:1628-36.

Bergman R, Parkes. "Systematic review: the use of mesalazine in inflammatory bowel disease". *Aliment Pharmacol Ther.* 2006;23:841-55.

Tromm A, Bunganic I, Tomsova E, et al. "Double-blind, double-dummy, randomised, multicentre study to compare the efficacy and safety of oral budesonide (9 mg) and oral mesalazine (4.5 g) in moderately active Crohn's disease patients". *Gastroenterology* 2009;139(Suppl1):391

Akobeng AK, Thomas AG. "Enteral nutrition for maintenance of remission in Crohn's disease". *Cochrane Database Syst Rev* 2007;3:CD005984.

Steinhart A.H., Forbes A., Mills E.C., et al. "Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease". *Aliment Pharmacol Ther* 25, 2007: 1389–1399.

Marshall JK, Irvine EJ. "Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis". *Gut.* 1997;40:775-81.

Truelove SC, Witts LJ. "Cortisone in ulcerative colitis. Final report on a therapeutic trial". *BMJ.* 1955;2:1041-8.

Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. "Oral budesonide for induction of remission in ulcerative colitis". *Cochrane Database Syst Rev* 2010 [CD007698-CD007698].

Turner D, Walsh CM, Steinhart AH, Griffiths AM. "Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression". *Clin Gastroenterol Hepatol.* 2007;5:103-10

Otley A, Steinhart AH. "Budesonide for induction of remission in Crohn's disease". *Cochrane Database Syst Rev* Oct 19 2005(4): CD000296 Review.

Benchimol EI, Seow CH, Otley AR, Steinhart AH. "Budesonide for maintenance of remission in Crohn's disease". *Cochrane Database Syst Rev* 2009;1:CD002913.

Rahimi R, Nikfar S, Rezaie A, Abdollahi M. "A Meta-analysis of antibiotic therapy for active ulcerative colitis". *Dig Dis Sci.* 2007;52:2920-5.

Selby W, Pavli P, Crotty B. "Two-year combination antibiotic therapy with clarithromycin, rifabutin, and cefazolin for Crohn's disease". *Gastroenterology* 2007;132:2313–9.

Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *The American Journal of Gastroenterology.* 2018;113(4):481-517. 10.1038/ajg.2018.27

Cantoro L, Di Sabatino A, Papi C, Margagnoni G, Ardizzone S, Giuffrida P, et al. The Time Course of Diagnostic Delay in Inflammatory Bowel Disease Over the Last Sixty Years: An Italian Multicentre Study. *J Crohns Colitis.* 2017;11(8):975-80. 10.1093/ecco-jcc/jjx041 28333328

Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, et al. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. *J Crohns Colitis.* 2015;9(8):601-6. 10.1093/ecco-jcc/jjv067 25908718

Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. *Inflamm Bowel Dis.* 2015;21(8):1982-92. 10.1097/mib.0000000000000392

10.1097/MIB.0000000000000392.

Sanz J, Juanola Roura X, Seoane-Mato D, Montoro M, Gomollón F. Screening of Inflammatory Bowel Disease and Spondyloarthritis for Referring Patients Between Rheumatology and Gastroenterology. *Gastroenterol Hepatol.* 2018;41(1):54-62. 10.1016/j.gastrohep.2017.03.012

10.1016/j.gastrohep.2017.03.012. Epub 2017 Sep 4.

Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. *Journal of Crohn's and Colitis.* 2017;11(1):3-25. 10.1093/ecco-jcc/jjw168

Reinisch S, Schweiger K, Pablik E, Collet-Fenetrier B, Peyrin-Biroulet L, Alfaro I, et al. An index with improved diagnostic accuracy for the diagnosis of Crohn's disease derived from the Lennard-Jones criteria. *Aliment Pharmacol Ther.* 2016;44(6):601-11. 10.1111/apt.13727 27466047

Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European Evidence-based

Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. *Journal of Crohn's and Colitis*. 2017;11(6):649-70. 10.1093/ecco-jcc/jjx008

Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. *J Crohns Colitis*. 2013;7(12):982-1018. 10.1016/j.crohns.2013.09.016 24184171

Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *Am J Gastroenterol*. 2015;110(9):1324-38. 10.1038/ajg.2015.233 26303131

Laine L, Kaltenbach T, Barkun A, McQuaid KR, Subramanian V, Soetikno R. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastroenterology*. 2015;148(3):639-51.e28. 10.1053/j.gastro.2015.01.031 25702852

Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G, et al. A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricture Crohn's Disease. *Inflamm Bowel Dis*. 2017;23(1):133-42. 10.1097/MIB.0000000000000988 28002130

Bruining DH, Zimmermann EM, Loftus EV, Jr., Sandborn WJ, Sauer CG, Strong SA. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. *Gastroenterology*. 2018;154(4):1172-94. 10.1053/j.gastro.2017.11.274 29329905

Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, et al. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. *J Crohns Colitis*. 2013;7(7):556-85. 10.1016/j.crohns.2013.02.020 23583097

Atkinson NS, Bryant RV, Dong Y, Maaser C, Kucharzik T, Maconi G, et al. WFUMB Position Paper. Learning Gastrointestinal Ultrasound: Theory and Practice. *Ultrasound Med Biol*. 2016;42(12):2732-42. 10.1016/j.ultrasmedbio.2016.08.026 27742140

Panes J, Bouzas R, Chaparro M, Garcia-Sanchez V, Gisbert JP, Martinez de Guereñu B, et al. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease. *Aliment Pharmacol Ther*. 2011;34(2):125-45. 10.1111/j.1365-2036.2011.04710.x 21615440

Chatu S, Subramanian V, Pollok RC. Meta-analysis: diagnostic medical radiation exposure in inflammatory bowel disease. *Aliment Pharmacol Ther*. 2012;35(5):529-39. 10.1111/j.1365-2036.2011.04975.x 22239831

Takenaka K, Ohtsuka K, Kitazume Y, Matsuoka K, Nagahori M, Fujii T, et al. Utility of Magnetic Resonance Enterography For Small Bowel Endoscopic Healing in Patients With Crohn's Disease. *Am J Gastroenterol*. 2018;113(2):283-94. 10.1038/ajg.2017.464 29257147

Rimola J, Planell N, Rodriguez S, Delgado S, Ordas I, Ramirez-Morros A, et al. Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging. *Am J Gastroenterol*. 2015;110(3):432-40. 10.1038/ajg.2014.424 25623654

Kucharzik T, Wittig BM, Helwig U, Borner N, Rossler A, Rath S, et al. Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. *Clin Gastroenterol Hepatol*. 2016. 10.1016/j.cgh.2016.10.040 27856365

Dotan I, Ron Y, Yanai H, Becker S, Fishman S, Yahav L, et al. Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study. *Inflammatory Bowel Diseases*. 2014 Dec 1;20(12):2247-59.

Brandse JF, Mould D, Smeekes O, Ashruf Y, Kuin S, Strik A, et al. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. *Inflammatory bowel diseases*. 2017;23(4):650-60.

Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip JM, et al. Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*. 2014;12(1):84.e2.

Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, et al. Optimizing Anti-TNF-alpha Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. *Clin*

Gastroenterol Hepatol. 2016 April 01;14(4):557.e2.

Paul S, Moreau AC, Del Tedesco E, Rinaudo M, Phelip J, Genin C, et al. Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. *Inflammatory Bowel Diseases*. 2014 Jul 1;20(7):1288-95.

Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. *Frontline Gastroenterology*. 2016 Oct;7(4):289-300.

West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude, C J. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. *Aliment Pharmacol Ther*. 2008 November 01;28(9):1122-6.

Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. *Gastroenterology*. 2009 November 01;137(5):1628-40.

Schulze H, Esters P, Hartmann F, Stein J, Christ C, Zorn M, et al. A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. *Scand J Gastroenterol*. 2018 March 21:1-7.

Ungar B, Kopylov U, Yavzori M, Fudim E, Picard O, Lahat A, et al. Association of Vedolizumab Level, Anti-Drug Antibodies, and alpha4beta7 Occupancy With Response in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol*. 2018 May 01;16(5):705.e7.

Papamichael K, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, et al. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. *Clin Gastroenterol Hepatol*. 2017 October 01;15(10):1588.e3.

Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. *Inflamm Bowel Dis*. 2014 November 01;20(11):1996-2003.

Papamichael K, Osterman MT, Siegel CA, Melmed GY, Dubinsky MC, Colombel JF, et al. Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care? *Gastroenterology*. 2018 March 01;154(4):1201-2.

Papamichael K, Vajravelu RK, Vaughn BP, Osterman MT, Cheifetz AS. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. *J Crohns Colitis*. 2018 March 24.

Bloem K, Hernandez-Breijo B, Martinez-Feito A, Rispens T. Immunogenicity of Therapeutic Antibodies: Monitoring Antidrug Antibodies in a Clinical Context. *Ther Drug Monit*. 2017 August 01;39(4):327-32.

Brandse JF, van den Brink, G R, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. *Gastroenterology*. 2015 August 01;149(2):5.e2.

Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. *Gut*. 2014 November 01;63(11):1721-7.

Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, et al. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis. *J Gastroenterol*. 2016 March 01;51(3):241-51.

Papamichael K, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, et al. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. *Clin Gastroenterol Hepatol*. 2016 April 01;14(4):543-9.

Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten, A, Billiet T, Baert F, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. *Clin Gastroenterol Hepatol*. 2015 March 01;13(3):531-8.

Papamichael K, Baert F, Tops S, Assche GV, Rutgeerts P, Vermeire S, et al. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis. *J Crohns Colitis*. 2016 July 11.